General Information

• HIV and Viral Hepatitis (Centers for Disease Control and Prevention – CDC)
• Training Manual for Treatment Advocates: Hepatitis C Virus and Coinfection with HIV (Treatment Action Group)
• An Overview of HIV/HCV Coinfection (HCV Advocate)

Selected Recent Articles

Note: Research on the HIV and hepatitis C virus (HCV) coinfection – and particularly the treatment of coinfection – is evolving rapidly.  Many articles and reports about HIV-HCV coinfection are being published each year, and information may become outdated quickly. For this reason, we have focused primarily on news from the past 3 years.

• Almost half of MSM with HIV/HCV co-infection have HCV in their rectal fluid.  (December 2016, AIDSmap)
•  

  HIV-Positive Men in San Diego Contract Hepatitis C at Increasing Rate.  (December 2016, Poz)

• Epclusa demonstrates manageable drug interaction profile with commonly used ART.  (September 2016, Healio)
• HCV/HIV coinfection contributes to mortality of patients awaiting LT [liver transplant].  (September 2016, Healio)
• HIV Meds Haven’t Prevented End-Stage Liver Disease in Those with Hepatitis.  (September 2016, Hepmag)
• 8-week Harvoni safe, effective in patients coinfected with HIV/HCV.  (September 2016, Healio)
• High HCV Levels in 33% of Semen Samples From Men with HIV and HCV.  (September 2016, HIV Treatment Alerts/TheBodyPro)
• Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive patients with viral hepatitis.  (September 2016, AIDSmap)
• Statins reduce risk of progression to cirrhosis in HIV/HCV-co-infected people.  (September 2016, AIDSmap)
• Perhaps Having HIV Doesn’t Always Raise Fibrosis Risk in Those With Hepatitis C.  (August 2016, Poz)
• Antiretroviral use shows no reduction in ESLD incidence.  (August 2016, Healio)
• For Injection Drug Users With HIV, Higher Risk of Liver/Kidney Disease — But Not Other Non-AIDS Ills.  (August 2016, TheBodyPro)
• HIV not a risk factor for fibrosis progression in people with hepatitis C.  (August 2016, AIDSmap)
• Statins Linked to Lower Risk of Cirrhosis in Those with HIV and Hepatitis C.  (August 2016, Poz)
• AbbVie 3D and 2D hepatitis C combos work well for people with HIV and HCV co-infection.  (August 2016, AIDSmap)
• Direct-acting antiviral ‘revolution’ improves treatment of HIV/HCV coinfection.  (August 2016, Healio)
• Hepatitis C Drives Non-AIDS Event Rate in 320 HIV Controllers.  (August 2016, TheBodyPro)
• HIV coinfection does not accelerate emergence of MDR-TB.  (August 2016, Healio)
• Hepatitis C Treatment Epclusa Works Well in Those With HIV.  (July 2016, Poz)
• HCV not associated with increase in HIV viral load among adults with HIV.  (July 2016, Healio)
• Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study. (July 2016, AIDSmap)
• Incidence of liver cancer is increasing in people with HIV/HCV co-infection.  (July 2016, AIDSmap)
• Enhanced Liver Fibrosis Marker Predicts Death in HIV/HCV-Positive Women.  (July 2016, TheBodyPro)
• HBV/HIV coinfection leads to poorer outcomes in hospitalized patients.  (June 2016, Healio)
• New HBV drugs and non-viral liver disease in HIV positive people.  (June 2016, HIV Treatment Bulletin)
• Sub-type C infection does not increase the risk of virologic failure when people are taking tenofovir-containing first-line ART.  (June 2016, AIDSmap)
• Among Those With HIV and Hep C, Real-World Harvoni Results Mirror Clinical Trial.  (May 2016, Hepmag)
• Conflicting Reports on Whether Having HIV Affects Hepatitis C Cure Rates.  (May 2016, Poz)
• Harvoni leads to high real-world virologic response rates in HIV/HCV coinfection.  (May 2016, Healio)
• Patients with HIV, HCV face risk for re-infection following antiviral treatment.  (May 2016, Healio)
• Does having HIV affect response to hepatitis C treatment?  (May 2016, AIDSmap)
• Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection.  (April 2016, AIDSmap)
• Study Exclusions Raise Questions About HCV Treatment Results in People with HIV.  (April 2016, The BodyPro)
• Coinfection with HIV, HCV may simplify access to antiviral treatment.  (April 2016, Healio)
• Response to DAA treatment in HCV/HIV coinfection varies.  (April 2016, Healio)
• Delaying Hepatitis C Treatment May Increase Liver-Related Death Risk in Those with HIV.  (April 2016, Poz)
• Gilead’s Upcoming Hep C Treatment, Sovaldi/Velpatasvir, Is Safe to Pair With Most HIV Meds.  (March 2016, Poz)
• Deferred HCV therapy in MSM with HIV/HCV increases risk for mortality. (March 2016, Healio)
• Global HIV/HCV burden exceeds 2 million, driven by PWID (March 2016, Healio); related coverage from Poz
• Health care rates, costs high in HCV/HIV patients who fail treatment. (March 2016, Healio)
• Hepatitis C Cure is Linked to Lowered Risk of Death, Kidney Disease and Diabetes in Those With HIV.  (March 2016, Poz)
• Poorly Controlled HIV is Independently Linked to Liver Fibrosis Progression in Those with and Without Hepatitis C. (March 2016, Poz)
• Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals.  (March 2016, AIDSmap)
• Coffee May Reduce the Risk of Death Among Those Coinfected with HIV and Hepatitis C.  (March 2016, Poz)
• Does Hep C Exposure Raise the Risk of Kidney Disease and Osteoporosis in People With HIV?  (March 2016, Poz)
• Frequent Cocaine Injection Among people with HIV and Hepatitis C Raises the Risk of Chronic Kidney Impairment. (March 2016, Poz)
• New HCV Infection Rate Rising in HIV-Positive Gay or Bisexual Men.  (March 2016, HIV Treatment Alerts)
• TE superior to FIB-4 for diagnosing HIV/HCV coinfection outcomes.  (February 2016, Healio)
• Harvoni effective for patients with HIV, acute HCV.  (February 2016, Healio)
• Treatment of patients with HIV, HCV requires planning, monitoring.  (February 2016, Healio)
• Health care rates, costs high in HCV/HIV patients who failed prior treatment.  (February 2016, Healio)
• Phase3 DAA trials do not reflect wider HIV/HCV population.  (January 2016, Healio)
• High Marks for Merck’s Hep C Treatment in Those with HIV. (December 2015, Hepmag)
• HIV No Longer Holds Down Hep C Cure Rates. (December 2015, Hepmag)
• Hepatitis C Initiative in Ryan White Clinics Findings from a Special Program of National Significance. (November 2015, Hepmag)
• HCV transmission during anal sex may happen without blood, study in HIV/HCV coinfected men finds. (November 2015, AIDSmap)
• People with HIV and HCV co-infection achieve high HCV cure rates with grazoprevir/elbasvir. (November 2015, AIDSmap)
• Statins Slow Liver Disease in People with HIV and HCV. (November 2015, Hepmag)
• Curing Hep C Lowers Risk of Death in Those Coinfected with HIV. (November 2015, Hepmag)
• Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection. (October 2015, AIDSmap)
• Sofosbuvir + daclatasvir demonstrates high cure rates for people with HIV and HCV co-infection. (October 2015, AIDSmap)
• Abacavir/lamivudine could be driving liver damage in ART-treated patients with HIV/HCV co-infection. (October 2015, AIDSmap)
• Fatty liver may contribute to higher risk of death for HIV/HCV co-infected people. (August 2015, AIDSmap)
• Cure Hep C and You May See Your Liver Health Improve. (August 2015, Hepmag)
• HIV providers less likely than hepatologists to screen for HCC. (August 2015, Healio)
• Hepatitis C cure associated with significant improvement in liver stiffness in people with HIV and HCV co-infection. (August 2015, AIDSmap)
• Mortality Greater, CD4 Count Gains Slower in HIV/HCV-Coinfected Patients. (August 2015, TheBodyPro)
• Hepatitis C Largely Explains Higher Mortality in Injection Drug Users With HIV. (August 2015, TheBodyPro)
• Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection. (July 2015, AIDSmap)
• Hep C Coinfection Increases Death Risk in Drug Users With HIV. (July 2015, Hepmag)
• Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment. (June 2015, AIDSmap)
• Acute HCV infections observed among HIV-negative gay men in London. (June 2015, AIDSmap)
• Harvoni and Sovaldi/Daclatasvir Safer to Mix With HIV Meds. (June 2015, Poz)
• High HCV infection rate in sub-Saharan Africa, with prevalence especially high in patients with HIV. (June 2015, AIDSmap)
• Harvoni added benefit for patients with HCV/HIV coinfection. (May 2015, Healio)
• Pot Lowers HIV/HCV-Coinfected People’s Insulin Resistance Risk. (May 2015, Poz)
• Outcomes poor among HIV/HCV coinfected kidney transplant recipients. (May 2015, Healio)
• Oral DAAs effective for HIV/HCV patients. (May 2015, Healio)
• Joint Pain Flares Among People With HIV, Hepatitis C or Both. (May 2015, Hepmag)
• Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients. (April 2015, AIDSmap)
• End-stage liver disease is a concern for people with HIV and hepatitis B or C co-infection. (April 2015, AIDSmap)
• Cannabis use reduces risk of insulin resistance in people with HIV/HCV co-infection. (April 2015, AIDSmap)
• Risk Factors for Hep C Acquisition Among HIV-Positive Gay Men. (April 2015, Hepmag)
• Adherence to a once-daily medication in hepatitis C mono-infected and HIV/HCV co-infected patients. (March 2015, Project Inform)
• High SVR rates in HIV/HCV co-infected patients with a fixed-dose regimen of ledipasvir/sofosbuvir. (March 2015, Project Inform)
• High SVR12 rates seen in HIV/HCV co-infected persons who take daclatasvir with sofosbuvir. (March 2015, Project Inform)
• The benefits of achieving SVR in HCV mono-Infected and HIV/HCV co-infected persons. (March 2015, Project Inform)
• Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people. (March 2015, AIDSmap)
• Delaying Hep C Therapy for HIV/HCV Coinfected People Is Risky. (March 2015, Poz)
• Coinfected People With Hep C May Have to Switch HIV Meds to Take Olysio. (March 2015, Poz)
• 96% Hep C Cure Rate for Harvoni in Those Coinfected With HIV. (March 2015, Poz)
• Two interferon-free regimens show high HCV cure rates for people with HIV and HCV co-infection. (February 2015, AIDSmap)
• HCV recurrence after SVR 20 times more frequent with HIV/HCV than HCV alone. (February 2015, NATAP)
• Patients with HIV/HCV may require ART switch to receive Olysio. (February 2015, Healio)
• 98% Hep C Cure Rate For Harvoni in Those Coinfected With HIV. (February 2015, Hepmag)
• High Hep Cure Rates for Viekira Pak Among Those Coinfected With HIV. (February 2015, Hepmag)
• HIV Viral Rebounds Predict Fibrosis in HCV-Coinfected People. (February 2015, Hepmag)
• HIV/HCV Co-Infection News from the 2014 Liver Meeting.  (January-February 2015, Positively Aware)
• Hep C Doesn’t Apparently Lead to Cognitive Decline in People With HIV. (December 2014, Poz)
• Success for ‘3D’ Combo in Those Coinfected with HIV. (December 2014, Hepmag)
• AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people withHIV co-infection. (November 2014, AIDSmap)
• Harvoni Cures Almost All People With Hep C Coinfected With HIV. (November 2014, Poz)
• High Post-Liver Transplant Survival Rates for People With HIV. (November 2014, Poz)
• Merck’s grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection. (November 2014, AIDSmap)
• People living with HIV have high survival rates after liver transplants due to HCC. (November 2014, AIDSmap)
• High Success For Harvoni Treating Coinfected Genotype 1. (November 2014, Hepmag)
• Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection. (November 2014, AIDSmap)
• For HIV/HCV Coinfected Patients, 3D With Ribavirin Highly Effective. (September 2014, TheBodyPro)
• HIV-Positive People in Care Are Infrequently Retested for Hep C. (September 2014, Poz)
• People living with HIV in the U.S. are infrequently screened for HCV. (September 2014, AIDSmap)
• High Hep C Cure Rates for ‘3D’ Combo in People Coinfected With HIV. (September 2014, Poz)
• Sovaldi-Ledipasvir Pill Safe With Major HIV Meds. (September 2014, Hepmag)
• HIV/HCV-Coinfected Individuals at Greater Risk of Osteoporosis and Fractures. (August 2014, TheBodyPro)
• People With Both HIV & Hep C Have Raised Risk of Bone Loss. (July 2014, Poz)
• HIV/HCV co-infection associated with increased risk of osteoporosis and fractures. (July 2014, AIDSmap)
• NIH Seeks Applications For HIV and Viral Hepatitis Co-Infection Research Funding. (June 2014, Hepmag)
• Gilead’s Sovaldi-Ledipasvir Pill Safe With Major HIV Drugs. (May 2014, Poz)
• Alcohol Is Very Risky for Those Coinfected With HIV and Hep C. (May 2014, Poz)
• Even moderate drinking increases risk of advanced liver fibrosis for people with HIVand HCV co-infection. (May 2014, AIDSmap)
• Perfect HIV/HCV Coinfection Cure Rate for Sovaldi/Ledipasvir. (April 2014, Poz)
• Sovaldi & Ribavirin Is Effective for HIV/HCV Population. (March 2014, Poz)
• Merck combination suppresses HCV in mono-infected and co-infected patients. (March 2014, AIDSmap)
• Those with Both HIV and Hepatitis C Face High Liver Cancer Rates. (March 2014, Poz)
• Coinfected With HIV and Hep C? Time To Party Like It’s 1996. (March 2014, Poz)
• Post-Transplant Survival Lower with HIV and HCV-1 Than with HCV-1 Alone. (March 2014, NATAP)
• HIV Transmission Bottleneck Offers Clue to HCV Epidemic in HIV+ MSM. (March 2014, NATAP)
• HIV No Bar to HCV Therapy With New Agents. (March 2014, MedPage Today)
• SVR12 72% With Faldaprevir Plus PegIFN/RBV in Naives With HCV/HIV. (March 2014, NATAP)
• Incivek Improves Outcomes for HIV/HCV Coinfected Gay Men. (November 2013, Poz)
• Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection. (November 2013, AIDSmap)
• Sofosbuvir + ribavirin produces sustained response in 76% of genotype 1 HIV/HCV co-infected people. (November 2013, AIDSmap)
• Sofosbuvir and Ribavirin Fare Well Among HIV-HCV Coinfected. (November 2013, Poz)
• HCV reinfection is common among HIV-positive gay men in Europe. (October 2013, AIDSmap)
• Simeprevir with interferon effective for HIV/HCV co-infected people with genotype 1 hepatitis C. (October 2013, AIDSmap)
• Predicting response to acute hepatitis C treatment in HIV/HCV co-infected people. (October 2013, AIDSmap)
• Liver fibrosis linked to immune activation in HIV/HCV co-infected women. (October 2013, AIDSmap)
• Hep C Genotype 3 Treatment Results Same in HIV Coinfection. (October 2013, Poz)
• Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people. (September 2013, AIDSmap)
• Interferon response reduces liver disease and death in HIV/HCV co-infected people. (September 2013, AIDSmap)
• Decompensated cirrhosis increases risk of liver cancer for people with HIV and viral hepatitis co-infection. (September 2013, AIDSmap)
• People with HIV/HCV-co-infection and advanced liver fibrosis can rapidly develop decompensated liver disease. (September 2013, AIDSmap)
• Treat Hep C if HIV-Coinfected Have Advanced Fibrosis. (August 2013, Poz)
• High proportion of Canadian patients with HIV-HCV co-infection and liver cirrhosis are not having ultrasounds to check for liver cancer. (August 2013, AIDSmap)
• No Link Between Pot and Liver Disease in HIV/Hep C Coinfected. (August 2013, Poz)
• A quarter of HIV/HCV-co-infected people in EuroSIDA have received HCV therapy. (August 2013, AIDSmap)
• Smoking cannabis does not accelerate progression of liver disease in people with HIV/HCV co-infection. (July 2013, AIDSmap)
• Investigators identify genetic profile associated with better treatment outcomes in people with HIV/HCV co-infection. (July 2013, AIDSmap)
• HIV/HCV co-infected people can do well on hepatitis C triple therapy despite contraindications. (July 2013, AIDSmap)
• Hep B or C Coinfection Spells Worse Response to HIV Meds. (July 2013, Poz)
• Victrelis Ups Hep C Cure Rates in Those Coinfected With HIV. (July 2013, Poz)
• Fibroscan accurately predicts liver decompensation and death in HIV/HCV co-infected people. (July 2013, AIDSmap)
• Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss. (July 2013, AIDSmap)
• Hepatitis C reinfection occurs frequently among gay men living with HIV in London. (July 2013, AIDSmap)
• Hyaluronic acid levels can predict risk of serious liver events in people living with HIV and hepatitis B or C co-infection. (June 2013, AIDSmap)
• Liver Transplants Are a Viable Option for People With HIV. (May 2013, Poz)
• Ryan White Program Addressing Coinfection with Viral Hepatitis. (May 2013, Poz)
• Hep C Transmission Among Gay Men Dates Back Decades; HIV a Major Risk Factor. (April 2013, Poz)
• Elevated prevalence of HIV and viral hepatitis in men injecting anabolic steroids. (April 2013, AIDSmap)
• Hepatitis C epidemic in US gay men is decades old. (April 2013, AIDSmap)
• HIV and HIV/HCV Boost Risk of Venous Thromboembolism in Large Veterans Cohort. (March 2013, NATAP)
• Framingham Score May Underestimate CHD Risk With HIV, HCV, and HIV/HCV. (March 2013, NATAP)
• Adding telaprevir improves acute hepatitis C treatment for HIV-positive men. (March 2013, AIDSmap)
• Faldaprevir ups interferon response in HIV/HCV co-infection. (March 2013, AIDSmap)
• Simeprevir pushes HCV cure rate above 75% for HIV/HCV co-infection. (March 2013, AIDSmap)
• Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study. (March 2013, NATAP)
• French study reports real-world data on use of telaprevir and boceprevir in people with HIV and hepatitis C co-infection. (March 2013, AIDSmap)
• Study shows value of hepatitis C therapy for HIV co-infected patients with compensated cirrhosis. (February 2013, AIDSmap)
• HIV Accelerates Liver Fibrosis by Nearly a Decade Among People With Hep C. (February 2013, Poz)
• New Evidence Suggests Hepatitis C Transmits Sexually Among HIV-Positive Gay Men. (February 2013, Poz)
• Triple trouble: infection with hepatitis B increases risk of death for people with HIV and hepatitis C co-infection. (February 2013, AIDSmap)
• More evidence of sexual transmission of hepatitis C among HIV-positive gay men in the US. (February 2013, AIDSmap)
• Spanish research shows that liver stiffness can predict outcomes in people co-infected with HIV and hepatitis C. (January 2013, AIDSmap)
• Co-infection with hepatitis B or C is a risk factor for reduced bone mineral density among women with HIV. (January 2013, AIDSmap)